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The real mechanism involved in trisomies and leukemogenesis remains unknown and
more information about this connection is essential, but unfortunately the clinical outcome
and hematological profile of patients with isolated trisomy 11 and AML have not been
well characterized. Considering the limited data on the specific disease entity, the current
report describes two cases of de novo acute monocytic leukemia (AMoL) and isolated
+11, in which this event was further characterized. Rev. bras. hematol. hemoter.
2008;30(3):253-255.
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Introduction
Chromosomal trisomies are characterized by an
additional copy of genomic material. Isolated trisomies
(+8,+11,+13,+21) comprise 90% of all trisomies1 and 7% of
adult de novo acute myeloid leukemia (AML).2 Little is known
about the clinical and hematological characteristics of de
novo acute monoblastic leukemia (AMoL) patients with
isolated trisomy 11, but immunophenotypic studies have
shown that trisomy 11 and AML are associated with an early
myeloid precursor,3 probably as a result of a pluripotent stem
cell disorder being discovered in primary as well as in
secondary myelodysplastic syndromes (MDS)/AML. Sierra
and coworkers3 proposed that de novo AML with trisomy 11
can be considered a specific entity associated with poor
outcomes and characterized by morphology of blasts cells
with myelodysplastic characteristics. Concerning cytogenetic
results, isolated trisomy 11 is the third most common isolated
trisomy in de novo AML, reported in 5.7% of AML patients
with normal karyotypes, 37.5% of cases with trisomy 11 and
other cytogenetic abnormalities and 79% of cases with trisomy
as the sole karyotypic abnormality.4 In AML or MDS isolated
trisomy 11 occurs in less than 3% of all cases 4-7 often with no
full description of clinical and hematological features.8
Besides +11, abnormalities involving chromosome 11,
translocations, interstitial deletions and duplications are
reported in various hematologic disorders, especially MLL
Partial Tandem Duplication (MLL - PTD), which confers, both
in childhood and adult AML, a worse prognosis and
shortened overall and event free survival.9 Molecular studies
of AML with trisomy 11 have revealed a high incidence of
partial tandem duplication of the MLL gene11 but it is still
uncertain how MLL gene duplication and trisomy 11 arise
and how they are related during leukemogenesis. The aim of
this report is to describe, with clinical and laboratory data,
two cases of isolated trisomy 11 and de novo AMoL, to
provide more information about this event.
Case history and results
Case 1
A 59 year-old female patient was admitted to hospital in
February 2000 due to fever, fatigue and weight loss. Routine
blood analysis showed anemia (hemoglobin 5.2g/dL), white
blood cell count (WBC) of 0.31 x109/L with 82% of blast cells
and 12.6 x109/L platelets. Bone marrow aspiration presented
92% of monoblasts and immunophenotyping showed:
positive CD11c, CD13, CD14, CD15, CD33, CD38, CD45, CD65
and HLA-DR. Bone marrow karyotype showed 47,XX,+11[5]/
46,XX.12 The diagnosis of AMoL (poorly differentiated) by
WHO13 or AML M5a according to the FAB14 classification
was established. The patient was scheduled to a Dauno +
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AraC (3+7) regimen but complete remission was achieved
only after a second induction with AraC, VP16 and
Mitoxantrone. Consolidation was achieved with the last
regimen at the same doses. Intensification was not considered
due to the frail aspect (low Karnofsky index) of the patient,
but a maintenance regimen with Ara-C for 15 months was
administered. Seventeen months out of therapy the patient
relapsed and died due to sepsis.
Case 2
A 54 year-old female patient was admitted to the hospi-
tal because of abdominal pain, sickness, watery diarrhea and
skin infections in February 2001. She presented hepatomegaly
(8cm). Blood analysis showed anemia (hemoglobin 6.7g/dL),
WBC was 3.99x 109/L with 87% of blasts and 1.09 x109/L
platelets. Bone marrow aspiration showed 88% of monoblasts
and immunophenotyping showed positive CD4, CD11c,
CD13, CD15 and CD33. Bone marrow karyotype revealed
47,XX,+11/46,XX.12 The diagnosis of AMoL, poorly
differentiated by WHO 13 or AML M5a FAB14 was made. The
patient developed respiratory insufficiency and died before
the start of chemotherapy.
Discussion
Patients with trisomy 11 and AML are associated with
short first complete remission and poor response to
subsequent chemotherapeutic regimens.6,15 Due to the
variable clinical course and prognosis, they may be included
in the intermediate cytogenetics risk group for success of
induction and overall survival16 or in the unfavorable risk
group.17 It is currently unknown whether isolated trisomy 11
constitutes an independent prognostic factor. This numerical
chromosome change is not correlated with any specific WHO
subgroup of MDS/AML, despite, in previous studies, trisomy
11 has been associated with older age, M2 and M1 FAB
subtypes, high platelet count, low incidence (13-15%) of
patients with WBC counts (> 50x109/L) and short long term
disease free survival,4 it has been suggested that +11 is
especially associated with myelomonocytic proliferation.6
The patients here presented AMoL FAB M5, white
blood cell count > 20.000x109/L, platelet count >10×109/L and
were more than 50 years old. Acute monoblastic leukemias
(M5a and M5b) are considered aggressive diseases due to
their association with hyperleukocytosis, extra medullar and
gingival or cutaneous infiltration.6 These cases represented
1.3% (2/154) of all the AMLs admitted to the Department of
Hematology – Unifesp from 1995 to 2005. In studies, the
incidence ranges from 0.9% to 0.76% as the sole
abnormality.3,4
Approximately 90% of adults with sole +11 and AML
and 11% of adult patients with de novo AML and normal
cytogenetics carry a molecular rearrangement of the MLL
gene (mixed lineage leukemia or myeloid/lymphoid leukemia).7
This rearrangement occurs in the early phase of the disease
and is not a genetic event induced by chemotherapy.18
Caligiuri and colleagues7 did not find additional mutated MLL
genes in AML with trisomy 11 and proposed that the extra
copy of chromosome 11 containing the wild type allele
provides a selective growth or survival advantage over normal
cells.19 This is provocative and warrants further molecular
investigations of AML with trisomy 11 and the MLL gene,
as this may give useful information on the genetic
mechanisms leading to the formation of trisomies during
leukemogenesis.
Resumo
O mecanismo envolvido em trissomias e leucemogênese permane-
ce não esclarecido e mais dados sobre esta relação são fundamen-
tais, mas infelizmente os resultados clínicos e o perfil hematológico
dos pacientes com trissomia 11 isolada e LMA ainda não foram
bem caracterizados. Considerando o limitado número de informa-
ções, este relato descreve dois casos de leucemia monocítica de
novo e trissomia 11 onde este evento foi caracterizado. Rev. bras.
hematol. hemoter. 2008;30(3):253-255.
Palavras-chave: Trissomia 11; leucemia mielóide aguda;
cromossomos.
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